Health
Asia’s year in review: Who had it good — and who had it bad — in 2023
Curtis S. Chin, a former U.S. ambassador to the Asian Development Bank, is managing director of advisory firm RiverPeak Group. Jose B. Collazo is an analyst focusing on the Indo-Pacific region. Follow them on X at @CurtisSChin and @JoseBCollazo. As 2023 comes to a close, we take a look at the year that was in […]
Read More
CDC director says U.S. isn't yet near peak Covid or flu levels for the season
Winter officially begins Thursday, and with the cold season comes an expected rise in rates of flu and Covid, said Dr. Mandy Cohen, the director of the Centers for Disease Control and Prevention. The U.S. is seeing a “sharp increase” in flu levels right now, particularly in the south, Cohen said Wednesday in an interview. […]
Read More
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but highly effective treatments from Novo Nordisk […]
Read More
Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
Jim Cramer ran through all 33 stocks in his Charitable Trust portfolio during the December edition of the CNBC Investing Club’s Monthly Meeting. Source
Read More
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled […]
Read More
Coca-Cola recalled 2,000 cases of drinks due to potential contamination
Cans of Sprite and Fanta, beverages produced by the Coca-Cola Company, seen displayed in a supermarket. Alex Tai | Lightrocket | Getty Images The Food and Drug Administration disclosed the recall in a filing and said it began on Nov. 6. It encompasses 1,557 cases of 12-ounce cans of Sprite, 417 cases of Diet Coke, […]
Read More
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
An exterior view of Moderna’s clinical manufacturing facility. David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. Brian Snyder | Reuters Shares of Vertex jumped Wednesday after the company’s painkiller, which is being tested as an alternative to opioids, significantly decreased pain in a mid-stage trial. Those positive results for diabetes patients suffering […]
Read More